Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 2 Fold change (median) of genes after 4 weeks intervention with a mixture of c9t11 and t10c12 CLA, c9t11 CLA, and t10c12 CLA compared to control (LA) according to realtime PCR verification.

From: Isomer-specific effects of CLA on gene expression in human adipose tissue depending on PPARγ2 P12A polymorphism: a double blind, randomized, controlled cross-over study

 

MIX

C9T11 CLA

T10c12 CLA

 

Gene symbol [NCBI RefSeq]

all

Pro

Ala

all

Pro

Ala

all

Pro

Ala

 

Fatty acid transport and metabolism

         

PPARγ dependency

   ABCA9 [NM_080283.3]

-1.3*

-1.3*

    

-1.4*

  

n/a

   LDLR [NM_000527.3]

1.2**

1.8**

    

1.5**

1.5**

 

↑[85]

   CD36 [NM_001001547.1]

   

-1.2*

 

-1.6*

-1.3*

 

-1.2*

↑[65, 86]

   LIPE [NM_005357.2]

  

1.96†

     

1.8†

↑[23]

   CA3 [NM_005181.2]

      

-2.0**

-2.0*

 

n/a

   FASN [NM_004104.4]

 

1.5*

    

1.2*

1.4*

 

↑[87]

   SCD [NM_005063.4]

  

1.3*

   

1.5*

 

1.9*

↑[34, 88]

   FADS1 [NM_013402.3]

1.6*

1.6*

       

n/a

Transkription factors

          

   PPARG [NM_138711.3]

 

-1.4**a

1.3 b

       

   NFAT5 [NM_138713.2]

-1.5*

-1.6*

    

-1.6*

 

-1.9†

n/a

   CREB5 [NM_182899.3]

      

-1.5*

 

-1.9†

n/a

   EBF1 [NM_024007.3]

 

-1.5†

       

↑[89]

Adipokines

          

   ADIPOQ [NM_004797.29]

  

1.6†

     

1.5†

↑[90, 91]

   LEP [NM_000230.2]

 

-1.2 a

1.7†b

      

↓[92]

   NAMPT [NM_005746.2]

        

-1.6*

= [62]

   THBS1 [NM_003246.2]

   

1.5**

1.3*

1.5*

   

↓[64] ↑[65]

Insulin signaling

          

   IGF1 [NM_001111284.1]

 

-1.5†

    

-1.2**

-1.2*

 

↓ [93]

   SLC2A4 [NM_001042.2]

1.3*

 

1.5†

      

↑[94]

   SORBS1 [NM_001034954.1]

 

-1.2*

       

↑[74]

   PIK3R1 [NM_181523.1]

 

-1.6†

       

↑[95]

Others

          

   HPGD [NM_000860.3]

-1.3**

 

-1.4**

     

-1.6*

See text

   API5 [NM_006595.2]

      

-1.3†

 

-1.5*

n/a

   CD74 [NM_001025158.1]

 

1.2*

       

n/a

   UCP2 [NM_003355.2]

1.14*

       

1.8†

↑[79]

   IL6ST [NM_175767.1]

-1.3*

     

-1.5†

 

-1.8†

n/a

  1. Comparison of CLA interventions and control (Wilcoxon test): *p < 0.05; **p < 0.001; † marks values with a tendency p ≤ 0.1 and more than +/- 1.5 fold change. Letters a and b indicate significant differences (p < 0.05) between effects in PPARγ2Pro12Pro (Pro; n = 23) and PPARγ2Ala12Ala (Ala; n = 11) carriers after the CLA mixture supplementation (Mann-Whitney U test).